<DOC>
	<DOCNO>NCT02266173</DOCNO>
	<brief_summary>This Phase IV , prospective , multicenter , non-interventional study ( regulatory post-marketing surveillance ) evaluate safety pertuzumab approximately 3000 participant metastatic locally unresectable recurrent breast cancer never receive chemotherapy anti-human epidermal growth factor receptor 2 ( HER2 ) therapy metastatic disease HER2 positivity Korea . Participants administer pertuzumab accord medical opinion doctor charge surveillance register study treat pertuzumab approval condition product Korea .</brief_summary>
	<brief_title>Observational Study Pertuzumab Safety Participants With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<criteria>Participants metastatic locally unresectable recurrent breast cancer never receive chemotherapy antiHER2 therapy metastatic disease HER2 positivity HER2positive , locally advanced , inflammatory , early stage breast cancer ( great [ &gt; ] 2 centimeter [ cm ] diameter ) participants never receive chemotherapy surgery breast cancer Hypersensitivity pertuzumab ( Perjeta ) excipients Contraindications Perjeta accord SmPC Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>